Targeting The Oncoprotein MDMX As A Novel Treatment For Triple Negative Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$561,672.00
Summary
Breast cancer (BrCa) is a leading cause of cancer death in women worldwide. BrCas unable to respond to current therapies have the worst outcomes. We propose a novel strategy to treat these cancers, based on our new findings. Our two protein targets are: (1) MDMX, that we found drives BrCa with its partner, (2) mutant p53, which causes cancer spread. We plan to directly target these drivers of aggressive BrCas, using new drugs that individually show great promise in trials in a number of cance
A Novel Approach For Treating B-cell Lymphoma By Inhibition Of The E3 Ligase E6AP
Funder
National Health and Medical Research Council
Funding Amount
$624,846.00
Summary
B-cell lymphoma is the most common type blood cancer diagnosed in Australia, and Australia's fifth most common cancer. Despite remarkable advances in diagnosis and treatment, lymphoma continues to rank as a leading cause of cancer-related mortality. Our pilot studies reveal a novel approach to treatment of B-cell lymphoma by inhibiting an enzyme that destroys our natural mechanism of defense against cancer. In this study we will test the efficacy of this novel treatment.